Welcome

T2D is a major risk factor for micro- and macrovascular complications. It doubles CV risk, increases the risk of kidney disease and reduces life expectancy. Addressing the burden of CV events is at the core of diabetes care.

The ACROSS T2D educational slide modules examine cardiovascular and renal disease in patients with T2D.
 

Disease State

SEE ALL

Therapeutic Management

SEE ALL
  • view presentation
    Use of SGLT2 inhibitors in primary care

    This module outlines SGLT2 inhibitor CVOT data, safety information and

  • view presentation
    Practical guidance on the use of SGLT2 inhibitors in patients with T2D during Ramadan

    This module summarises current practical guidance, evidence and recomm

  • view presentation
    Diabetes and COVID-19

    This module summarises recent guidance for healthcare professionals

Cardiovascular Outcomes Trials

SEE ALL